# A rare case of symmetrical drug‐related intertriginous and flexural erythema with tamoxifen use

## TL;DR

This paper reports a rare skin condition caused by tamoxifen, highlighting the importance of recognizing it to prevent severe complications.

## Contribution

The paper presents a new case of SDRIFE linked to tamoxifen, expanding the known side effects of this drug.

## Key findings

- SDRIFE is a rare but serious side effect of tamoxifen.
- Discontinuing tamoxifen can resolve the condition.
- Clinicians should be aware of this potential complication.

## Abstract

Symmetrical drug‐related intertriginous and flexural erythema is characterized by a diffuse symmetric rash of the gluteal and intertriginous areas with only one published report of association with tamoxifen. It is imperative for clinicians to recognize tamoxifen‐induced SDRIFE to avoid life‐threatening dermatologic complications, which can be resolved with discontinuation of tamoxifen.